VERITAS IN SILICO INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,181 JPY | +3.32% |
|
+3.42% | 0.00% |
| 05-07 | Certain Common Stock of Veritas In Silico Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024. | CI |
| 02-08 | Veritas In Silico Inc. has completed an IPO in the amount of ¥800 million. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| 1 day | +3.32% | ||
| 1 week | +3.42% | ||
| Current month | +2.52% | ||
| 1 month | -0.34% | ||
| 3 months | -36.44% |
1 week
1 039.00
1 208.00
1 month
1 024.001 238.00
Current year
1 024.003 475.00
1 year
1 024.003 475.00
3 years
1 024.003 475.00
5 years
1 024.003 475.00
10 years
1 024.003 475.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shingo Nakamura
FOU | Founder | 52 | 16/11/16 |
| Chief Administrative Officer | 56 | 31/05/18 | |
Takashi Kamimura
COO | Chief Operating Officer | 68 | 31/03/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Kamimura
COO | Chief Operating Officer | 68 | 31/03/17 |
Shingo Nakamura
FOU | Founder | 52 | 16/11/16 |
| Director/Board Member | 57 | 31/07/19 |
Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 47.16M | |
| +48.54% | 56.87B | |
| +37.15% | 39.72B | |
| -6.02% | 39.27B | |
| -6.90% | 28.73B | |
| +12.97% | 26.21B | |
| -16.91% | 19.79B | |
| +31.71% | 12.28B | |
| +28.18% | 12.23B | |
| +0.38% | 12.12B |
- Stock Market
- Equities
- 130A Stock